ATC Group: M09AX15 Delandistrogene moxeparvovec

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of M09AX15 in the ATC hierarchy

Level Code Title
1 M Musculo-skeletal system
2 M09 Other drugs for disorders of the musculo-skeletal system
3 M09A Other drugs for disorders of the musculo-skeletal system
4 M09AX Other drugs for disorders of the musculo-skeletal system
5 M09AX15

Active ingredients in M09AX15

Active Ingredient Description
Delandistrogene moxeparvovec

Delandistrogene moxeparvovec is the recombinant gene therapy product that is comprised of a non-replicating, recombinant, adeno-associated virus (AAV) serotype rh74 (AAVrh74) capsid and a ssDNA expression cassette flanked by inverted terminal repeats (ITRs) derived from AAV2. The cassette contains: 1) an MHCK7 gene regulatory component comprising a creatine kinase 7 promoter and an α-myosin heavy chain enhancer, and 2) the DNA transgene encoding the engineered delandistrogene moxeparvovec micro-dystrophin protein.

Related product monographs

Title Information Source Document Type  
ELEVIDYS Suspension for solution for infusion FDA, National Drug Code (US) MPI, US: SPL/PLR

Medicines in this ATC group

United States (US)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.